Raundhal, Mahesh http://orcid.org/0000-0001-8175-2957
Ghosh, Shrestha
Myers, Samuel A.
Cuoco, Michael S.
Singer, Meromit
Carr, Steven A.
Waikar, Sushrut S.
Bonventre, Joseph V. http://orcid.org/0000-0001-7144-386X
Ritz, Jerome
Stone, Richard M.
Steensma, David P.
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Glimcher, Laurie H. http://orcid.org/0000-0002-4971-0404
Funding for this research was provided by:
Dana-Farber Cancer Institute
Edward P. Evans Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24-CA210986, U01 CA214125)
U.S. Department of Health & Human Services | National Institutes of Health (1P50CA206963, 2P01CA066996)
Article History
Received: 10 August 2020
Accepted: 3 February 2021
First Online: 22 March 2021
Change Date: 14 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-021-01031-y
Competing interests
: An invention disclosure has been filed based on the data generated in this study. From 4 August 2020, Meromit Singer has been an employee of Guardant Health. S.S.W. has served on the steering committee of a GSK trial on an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, as a potential treatment for anemia associated with CKD; S.S.W. has also received consulting fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluewer, GE Health Care, Allena Pharmaceuticals, Mass Medical International, JNJ, Venbio, Strataka, Takeda, Cerus and Pfizer. D.P.S. has served on independent data safety monitoring committees for clinical trials supported by Takeda, Astex, Janssen and Onconova; has consulted for Celgene and Daiichi Sankyo; and has received research support (to the institution) for clinical trials sponsored by Aprea, H3 Biosciences, Syros and Astra Zeneca. J.R. reports research funding from Amgen, Equillium and Kite Pharma; and consulting income from Aleta Biotherapeutics, Avrobio, Celgene, Falcon Therapeutics, LifeVault Bio, Rheos Medicines, Talaris Therapeutics and TScan Therapeutics. R.M.S. has served on independent data safety monitoring committees for trials supported by Celgene, Takeda and Argenix; has consulted for AbbVie, Actinium, Agios, Amgen, Arog, Astellas, Astra Zeneca, Biolinerx, Celgene, Daiichi Sankyo, Fujifilm, Janssen, Juno, Macrogenics, Novartis, Ono, Orsenix, Pfizer, Roche, Stemline, Sumitomo, Takeda and Trovagene; and has received research support (to the institution) for clinical trials sponsored by AbbVie, Agios, Arog and Novartis. S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs and Seer and is a scientific advisor to Pfizer and Biogen. A.R. is a Scientific Advisory Board member of Thermo Fisher Scientific, Neogene Therapeutics, Asimov and Syros Pharmaceuticals. A.R. is a cofounder of and equity holder in Celsius Therapeutics and an equity holder in Immunitas. From 1 August 2020, A.R. has been an employee of Genentech. L.H.G. is a former Director of Bristol-Myers Squibb and the Waters Corporation and is currently on the board of directors of and holds equity in GlaxoSmithKline Pharmaceuticals and Analog Devices. She also serves on the scientific advisory boards of Repare Therapeutics, Abpro Therapeutics and Kaleido Therapeutics. S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs, and Seer and is a scientific advisor to Pfizer and Biogen. All other authors declare no competing interests.